Analyst Ratings For Protagonist Therapeutics (NASDAQ:PTGX)
Today, BTIG Research initiated coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy with a price target of $36.00.
There are 4 buy ratings on the stock.
The current consensus rating on Protagonist Therapeutics (NASDAQ:PTGX) is Buy (Score: 3.00) with a consensus target price of $29.00 per share, a potential 124.46% upside.
Some recent analyst ratings include
- 7/21/2017-BTIG Research initiated coverage with a Buy rating.
- 9/6/2016-Leerink Swann initiated coverage with a Outperform rating.
- 9/6/2016-Barclays PLC initiated coverage with a Overweight rating.
- On 7/10/2017 David Y. Liu, Insider, sold 3,500 with an average share price of $12.68 per share and the total transaction amounting to $44,380.00. View SEC Filing
- On 8/16/2016 Armen Shanafelt, Director, bought 583,333 with an average share price of $12.00 per share and the total transaction amounting to $6,999,996.00. View SEC Filing
Recent Trading Activity for Protagonist Therapeutics (NASDAQ:PTGX)
Shares of Protagonist Therapeutics closed the previous trading session at 12.92 0.00 0.00% with 123,887 shares trading hands.
